Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)โข Click on a phase to view related trials
VTP-1000 in Adults With Celiac Disease
- Conditions
- Celiac Disease
- Interventions
- Other: Matched Placebo
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT06310291
- Locations
- ๐บ๐ธ
Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
๐บ๐ธClinical Research Institute of Michigan, Clinton Township, Michigan, United States
๐บ๐ธWest Michigan Clinical Research Center, Wyoming, Michigan, United States
Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT05617040
- Locations
- ๐บ๐ธ
Cornell University, New York, New York, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธColumbia University Irving Medical Center, New York, New York, United States
Efficacy of VTP-300 in Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT05343481
- Locations
- ๐ญ๐ฐ
Prince Of Wales Hospital, Hong Kong, Hong Kong
๐จ๐ณDalin Tzu Chi Hospital, Chiayi City, Taiwan
๐จ๐ณChang Gung Memorial Hospital Kaohsiung, Kaohsiung, Taiwan
First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
- Conditions
- Hepatitis B
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT04778904
- Locations
- ๐ฐ๐ท
Pusan National University Hospital, Busan, Korea, Republic of
๐ฐ๐ทKyungpook National University Hospital, Daegu, Korea, Republic of
๐ฐ๐ทKeimyung University Dongsan Hospital, Daegu, Korea, Republic of
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
- Conditions
- HPV InfectionCIN1
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 108
- Registration Number
- NCT04607850
- Locations
- ๐ง๐ช
UZA, Antwerp, Belgium
๐ง๐ชErasme Hospital, Brussels, Belgium
๐ง๐ชUZ Brussel, Brussels, Belgium
- Prev
- 1
- 2
- Next
News
Biopharma Job Market Shows Signs of Recovery Despite Continued Layoffs in 2024
Biopharma job postings declined 16% year-over-year in Q4 2024, with at least 24,000 industry professionals laid off throughout the year, including major cuts at Johnson & Johnson, Bristol Myers Squibb, and Bayer.
Imdusiran, VTP-300, and Nivolumab Combination Shows Promise in Chronic Hepatitis B
A Phase 2a trial shows that imdusiran, VTP-300, and low-dose nivolumab led to significantly greater HBsAg declines in chronic hepatitis B patients.